Medical Condition News

RSS

New method allows for concurrent treatment of spinal tumors and stabilization of the spine

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

Cancer Research UK awards £12 million to 10 exceptional researchers

Cancer Research UK has given a number of prestigious grants to new investigators who are set to become the eminent cancer scientists of the future.

11 Jul 2011

Research validates SpinalCyte's core technology to regrow the spinal disc

SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the publication of its research completed with Rice University, titled, "Chondrogenic Differentiation of Neonatal Human Dermal Fibroblasts Encapsulated in Alginate Beads with Hydrostatic Compression Under Hypoxic Conditions in the Presence of Bone Morphogenetic Protein-2".

11 Jul 2011

Fibrin key to protection during gram-negative sepsis

New research from the Trudeau Institute may help to explain why anticoagulant therapies have largely failed to extend the lives of patients with sepsis. The study was led by Deyan Luo, a postdoctoral fellow in Stephen Smiley's laboratory. It shows that fibrin, a key product of the blood clotting process, is critical for host defense against Yersinia enterocolitica, a gram-negative bacterium that causes sepsis in humans and experimental mice.

11 Jul 2011

New corticosteroid with cream-like base

Upsher-Smith Laboratories, Inc. announced the launch of Trianex 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.

11 Jul 2011

FDA clears TearScience's LipiFlow Thermal Pulsation System for evaporative dry eye

TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its LipiFlow Thermal Pulsation System for the treatment of meibomian gland dysfunction (MGD), also known as evaporative dry eye.

11 Jul 2011

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

11 Jul 2011

Scientists study neuronal excitation to treat neurological disorders

Oh, the challenges of being a neuron, responsible for essential things like muscle contraction, gland secretion and sensitivity to touch, sound and light, yet constantly bombarded with signals from here, there and everywhere.

11 Jul 2011

Endosense completes first patient case utilizing new prototype software

Endosense, a Swiss medical technology company, has announced completion of the first patient case utilizing prototype software that integrates the contact-force data provided by Endosense's TactiCath force-sensing ablation catheter with Siemens Healthcare's electrophysiology solutions.

11 Jul 2011

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.

11 Jul 2011

Pain Practice journal publishes Vertos mild procedure clinical study data on LSS

Medical device company Vertos Medical Inc. has announced that one-year post-study follow-up data on its mild procedure for lumbar spinal stenosis (LSS) have been published in the peer-reviewed journal Pain Practice.

11 Jul 2011

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt in Mexico.

11 Jul 2011

Medical Condition News

New method allows for concurrent treatment of spinal tumors and stabilization of the spine

Cancer Research UK awards £12 million to 10 exceptional researchers

Research validates SpinalCyte's core technology to regrow the spinal disc

Fibrin key to protection during gram-negative sepsis

New corticosteroid with cream-like base

FDA clears TearScience's LipiFlow Thermal Pulsation System for evaporative dry eye

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Scientists study neuronal excitation to treat neurological disorders

Endosense completes first patient case utilizing new prototype software

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Pain Practice journal publishes Vertos mild procedure clinical study data on LSS

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

New radiofrequency ablation system for treating spinal tumors

People with long term debilitating physical illness demonstrate mental resilience

Randox launches Lab Tests Blog

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News